inflammatory bowel disease

Scientists develop hydrogel to directly target disease sites in inflammatory bowel disease

Researchers have developed a hydrogel that selectively delivers drugs to inflamed tissue, which could pave the way for improved treatment options for patients with inflammatory bowel disease, according to a study published in Science Translational Medicine.…

3D printing: the future of manufacturing medicine?

As the pharmaceutical industry shifts from mass manufacture towards personalised medicine, 3D printing could become part of the drug production line.…

Crohn’s disease investigational drug shows promise, phase II trial shows

Mongersen, an investigational agent being developed by Celgene, has been tested in Crohn’s disease and researchers have seen clinical remission in some patients.…

Beethoven’s musical electrocardiograms

Could Beethoven have suffered from cardiac arrhythmia? His music suggests he could have.…

Optimising therapy for inflammatory bowel disease

How to tailor treatment for patients and ensure optimum management of Crohn’s disease and ulcerative colitis.…

Forces driving the evolution of biologics into biosimilars and biobetters

As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…

Doctors call for improvement of inflammatory bowel disease services

Doctors are calling for a national strategy for inflammatory bowel disease so that it receives the same attention as other chronic conditions such as diabetes.…

Genetics plays a role in drug-induced pancreatitis

New research identifies a genetic variant that confers increased susceptibility to drug-induced pancreatitis.…

TNF-α antagonists not linked with cancer in Danish study

The use of tumour necrosis factor alpha (TNF-α) antagonists to treat inflammatory bowel disease (IBD) is not associated with an increased risk of cancer, analysis of a Danish registry indicates[1] . The analysis, conducted by researchers from Statens Serum Institute and …

Sunday morning musings on managing long-term conditions

“Community pharmacists are extremely famous, but we don’t know what you do.” These are the words of a delegate relaying the uninformed position of his voluntary sector colleagues. Wherever I am lately, this is the predominant question: do people really understand the role of pharma…